Soligenix, INC 10-Q quarterly reports

Soligenix, Inc. reported increased net losses in Q3 2025, driven by higher R&D expenses, but regained Nasdaq compliance through a recent public offering.

Soligenix, Inc. reported a significant increase in net loss for Q2 2025, raising substantial doubt about its ability to continue as a going concern despite ongoing clinical trial progress.

Soligenix reports a net loss for Q1 2025 and expresses concerns about its ability to continue as a going concern without securing additional funding.

Soligenix, Inc. released its third quarter 2024 financial results, highlighting advancements in its clinical programs and ongoing efforts to secure funding.

Soligenix reported a net loss of $3.56 million for the first half of 2024, while advancing its pipeline programs and securing additional funding.

Soligenix reported a net loss for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.